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A testing time for angiogenesis
 
ancer biology covers many hot-button topics—from cell 
cycle to metastasis to apoptosis—but this year it was 
angiogenesis that was filling the halls of The Moscone Center 
to bursting. Ever since Jim Watson’s stamp of approval hit the 
front page of 
 
The
 
 
 
New York Times
 
, angiogenesis has been the 
field to watch. But in recent months, some watchers have 
been quick to broadcast the early failures of antiangiogenic 
therapies in humans.
Angiogenesis researchers at the meeting noted several 
potential explanations for these failures. For starters, said Roy 
Herbst (M.D. Anderson Cancer Center, Houston, TX), 
“expectations were too high.” Angiogenesis inhibitors are 
expected to arrest tumors not shrink them: they should prevent 
further growth of blood vessels into a tumor rather than 
dissolve existing blood vessels. Sure enough, even in mouse 
models there was significant tumor growth after antiangiogenic 
therapies were started, and before those therapies began to 
reverse tumor growth. That pattern may be tolerable in a 
mouse, which can apparently withstand a tremendous tumor 
burden, but not in a human. Most patients, because of 
standard selection criteria, enter antiangiogenic trials with 
late-stage disease and only a few months to live.
But patient selection is only part of the story. Many 
investigators have now shown that different angiogenic factors 
are produced by different tumors at different times, in a way 
that is largely unpredictable even within a single tumor type 
or even single individual. Thus, a therapy that neutralizes 
only one angiogenic pathway is unlikely to be effective 
against many tumors.
This makes the work presented by Douglas Hanahan 
(University of California, San Francisco, CA) all the more 
C
 
An integrin that 
keeps it together
 
hen it comes to cancer prognosis, 
adhesion molecules are generally 
classified as either good cadherins or bad 
integrins. The cell–cell adhesion mediated 
by cadherins sticks potentially metastatic 
cells together so that they cannot spread, 
whereas the cell–extracellular matrix 
(cell–ECM) adhesion provided by 
integrins helps those same cancer cells 
to pull away from the pack and search out 
new sites for growth. But new results from 
Elizabeth Robinson, Siobhan Corbett, 
Ramsey Foty, and colleagues (University 
of Medicine and Dentistry New Jersey, 
New Brunswick, NJ) indicate that some 
integrins weigh in on the good side.
W
 
interesting. Hanahan first showed that a standard antiangiogenic 
treatment (an inhibitor of a VEGF receptor [VEGF-R]) was 
highly effective only when it was used against early stage 
disease. But he also found that a different inhibitor, named 
SU6668, was moderately effective against late stage disease, 
and highly effective when used in combination with the 
standard anti–VEGF-R treatment.
SU6668 is better at shutting down the PDGF receptor 
(PDGF-R) than the VEGF-R. Hanahan suggested that it was 
preventing a signaling event between endothelial cells and 
neighboring pericytes—signaling that is needed not for 
angiogenesis but to maintain the integrity of the newly 
established endothelium.
Other combination therapies were also mentioned at the 
meeting. Mike O’Reilly (Harvard Medical School, Boston, 
MA), the codiscoverer of the famous angiostatin, said that 
antiangiogenic therapies are now seen more as adjuvants to 
standard chemotherapies. “Angiogenesis inhibitors,” he said, 
“should not be considered the magic bullet.” 
 
 
 
Reference: Hellström, M., et al. 2001. 
 
J. Cell Biol.
 
 153:543–554.
Angiogenesis allows tumors to keep growing.
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Robinson already had clues from clinical 
studies that expression of the integrin 
 
 
 
5
 
 
 
1 was associated with a more positive 
prognosis. So she overexpressed the integrin 
The reaction to compression helps 
measure the cohesion of a tissue.
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in tissue culture cells, and measured its 
ability to stick cells together. The stickiness 
test involved measuring the resistance of 
cell aggregates to compression. Cells 
making 
 
 
 
5
 
 
 
1 were, she found, even more 
resistant to compression than cells expressing 
a cadherin.
This effect was dependent on the 
presence of the 
 
 
 
5
 
 
 
1 substrate fibronectin, 
but was not dependent on expression of 
a high level of cadherins. The 
 
 
 
5
 
 
 
1 is 
unique amongst the integrins in its ability 
to organize fibronectin into a matrix. This 
ability may allow it to convert multiple 
cell–ECM links into indirect cell–cell 
connections that can resist both compression 
forces and metastatic signals.
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Amoebas on the move
 
ven complete inhibition of a standard pathway for cancer cell movement might not be enough 
to prevent metastasis, according to Peter Friedl (University of Würzburg, Würzburg, Germany). 
He finds that cells inhibited for adhesive migration resort to an amoeboid movement that might 
be just as good at dispersing cancer cells.
This is not Friedl’s first indication that cancer cells have more than one migration strategy. He has 
seen cells moving in a variety of configurations—as solid strands, single files, cell clusters, and single 
cells—suggesting that a variety of mechanisms may be at work. Clustered cells, for example, “behave 
as a social unit,” he says, with adhesive integrins clustered and sometimes expressed only at the leading 
edge of the front-most cells.
This sociability can be blown apart with an anti–
 
 
 
1-integrin antibody. The clusters lose polarity, 
and cells detach and initiate an amoeboid form of crawling that resembles the movement strategy of 
human T cells. Rather than blazing a path through extracellular matrix, the cells squeeze through the 
tiny holes present in the intact matrix.
Friedl saw a similar form of amoeboid crawling after treatment of cancer cells with a cocktail of 
protease inhibitors. Most cancer cells move by chewing a path through the dense extracellular 
matrix, and Friedl can visualize the destruction that such cells leave in their wake. Many of the drugs 
that inhibit matrix metalloproteases are aimed at disrupting this process. But when Friedl completely 
disrupted this process with a cocktail of protease inhibitors, the cells merely switched to the amoeboid 
form of movement.
Clinical studies were already making it clear that inhibiting a single matrix metalloprotease might 
not be enough. As Friedl stated, cancer cells “have scissors, they have knives, they have saws, they have 
swords maybe, and it doesn’t make sense just to take away the scissors.” But now his work suggests 
that even the perfect inhibitor—one that takes away all those sharp implements—may not suffice.
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Multicellular metastases cluster integrins (red) at their front and leave gaps in the matrix at their rear.
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The Rb pretenders
 
s a model for human disease, mice lacking a copy of the Rb tumor suppressor are a dis-
tinct failure. For starters, they don’t get retinoblastoma. Even patches of eye cells that lack 
both copies of Rb don’t become tumors.
Tyler Jacks (Massachusetts Institute of Technology, Cambridge, MA) wondered if the Rb-related 
proteins p107 and p130 were filling in for Rb. This was consistent with the work of Anton Berns 
(Netherlands Cancer Institute, Amsterdam, Netherlands), who showed that mice lacking both 
Rb and p107 developed retinoblastomas. Perhaps the mouse versions of p107 and p130 were 
better than the human versions when it came to filling in for Rb and acting as tumor suppressors.
But Jacks’ recent experiments suggest another solution. When Jacks eliminated Rb abruptly 
in adult mice, using an inducible recombinase to flip the gene out of the chromosome, the 
mice rapidly developed retinoblastomas. Thus, it seems that p107 and p130 (and perhaps 
other proteins) can fill in for Rb, but only if Rb is absent throughout the life of the mouse. 
“Here’s one clear example of reprogramming following knockout,” said Jacks. Only when 
the cells lose Rb acutely, he said, is there insufficient time for compensation, allowing the 
immediate function of Rb to become apparent. 
 
 
 
Reference:  Sage, J., et al. 2000. 
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Coming back 
to life
 
enescent cells can be 
revived, according to 
results presented by Tyler 
Jacks (Massachusetts Institute 
of Technology, Cambridge, 
MA) and Christian Beausejour 
(Lawrence Berkeley National 
Laboratory, Berkeley, CA). 
Furthermore, says Beausejour, 
the ease with which cells can 
be revived depends on how 
far they have entered into 
the senescent program.
Beausejour, working with 
Judith Campisi, studied 
human fibroblasts that had 
shut down because repeated 
replication cycles had 
shortened their telomeres 
to a critical length. For some 
cells—those that had recently 
become senescent—all they 
needed to get going again 
was inactivation of the p53 
tumor suppressor. The 
primacy of this pathway is 
not surprising, as shortened 
telomeres are a form of DNA 
damage, and p53 is known 
to be an expert at detecting 
other forms of DNA damage.
If cells remained senescent 
for longer, however, 
then inactivating p53 was 
not enough. In this case, 
Beausejour had to turn off 
the Rb tumor suppressor 
pathway as well, suggesting 
that this pathway gets 
induced later in senescence. 
Jacks found that shutting off 
the Rb pathway was sufficient 
to reverse the senescence of 
mouse cells. Senescent 
mouse cells may not induce 
the p53 pathway, said 
Beausejour, because their 
telomeres are much longer 
than those of human cells.
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